GlassScriptPhysician profile
Mary C Keiser
NPI 1275642530
$3,870.59
in general payments reported to CMS, 2019-2025
17 companies · $807 in 2025
The $807 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $191 · 2021: $260 · 2022: $438 · 2023: $848 · 2024: $798 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,453.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $742.88 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $640.81 | 2019-2025 | Dailies Total1, Precision 1, Total30 |
| Sun Pharmaceutical Industries INC. | $459.33 | 2019-2025 | Cequa, Xelpros |
| Oyster Point Pharma, INC. | $380.72 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $316.30 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $280.20 | 2023-2025 | Miebo, Xiidra, Infuse |
| Johnson & Johnson Vision Care, INC. | $271.81 | 2022-2025 | Acuvue |
| Novartis Pharmaceuticals Corporation | $197.17 | 2020-2022 | |
| Glaukos Corporation | $168.62 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $160.46 | 2019-2021 | |
| Allergan, INC. | $53.62 | 2019-2022 | |
| Lombart Brothers, INC. | $43.49 | 2019 | |
| Shire North American Group INC | $41.41 | 2019 | |
| Abbvie INC. | $41.27 | 2022 | |
| Astellas Pharma US INC | $32.17 | 2023-2024 | Izervay |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $22.36 | 2024 | Vevye |
| Kala Pharmaceuticals, INC. | $17.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Keiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.